DCBO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Docebo is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The business looks fundamentally improving and analyst sentiment is constructive, but the stock is still in a 'show-me' phase with near-term headwinds and a mixed technical setup. Since you are unwilling to wait for a perfect entry, I would not buy aggressively here; the better call is to hold and wait for clearer post-earnings confirmation or a better price. If forced to choose today, the data supports a cautious hold rather than an outright buy.
DCBO closed at 20.87, slightly below the prior close of 20.96 after a strong regular-session move earlier in the day. The MACD histogram is positive at 0.35, but it is contracting, which suggests momentum is fading. RSI at 68.13 is near overbought but not extreme, and moving averages are converging, pointing to a pause/consolidation rather than a clean breakout trend. Support is around 19.45 pivot / 17.84 S1, while resistance sits near 21.06 R1 and 22.06 R2. Overall, the chart is neutral-to-slightly bullish short term, but not a high-confidence entry for a beginner long-term buy.
["Docebo is reporting Q1 earnings pre-market on 2026-05-08, creating an immediate event catalyst.", "The company has a 100% EPS and revenue beat rate over the past two years.", "Analyst estimate revisions have been favorable overall, with more upward than downward revisions in both EPS and revenue.", "Full-year revenue guidance was raised due to increased demand for its AI platform.", "Hedge funds are buying aggressively, with reported buying up 1100% over the last quarter."]
["Stifel, Morgan Stanley, and Scotiabank all cut price targets recently, showing reduced near-term expectations.", "Analysts explicitly describe the stock as a 'show-me story' and expect shares to remain rangebound in the near term.", "Docebo faces headwinds from AWS contract roll-off and ongoing Dayforce churn.", "Technical momentum is fading, with the MACD histogram contracting and moving averages converging.", "The stock trend model suggests weakness over the next week and month.", "No recent insider buying was reported, and insiders are neutral.", "No recent congress trading data was available."]
Latest reported quarter: 2025/Q4. Revenue rose 10.51% year over year to 63.04 million, net income jumped 125.47% year over year to 26.85 million, and EPS increased 156.41% year over year to 1.00. Gross margin slipped to 78.52%, down 1.62 points year over year. The latest quarter shows solid growth and strong profitability expansion, although margin pressure is a mild concern.
Wall Street remains constructive but less enthusiastic than before. Stifel kept a Buy rating but cut its target to $28 from $34. Morgan Stanley kept Equal Weight and lowered its target to $26 from $28, calling it a 'show-me story.' Scotiabank kept Outperform but cut its target to $25 from $32 and expects the stock to stay rangebound near term. Overall, the pros view is positive on the business, but the target cuts and cautious language show limited conviction for immediate upside.
